SCHEMBL644265

SCHEMBL644265

COc1cc(C(=O)O)ccc1Br

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.69
CA1 P00915 2/20 0.69
CA2 P00918 2/20 0.69
CA4 P22748 2/20 0.69
CA6 P23280 2/20 0.69
CA7 P43166 2/20 0.69
CA9 Q16790 2/20 0.69
CA14 Q9ULX7 2/20 0.69
TPMT P51580 1/20 0.69
HTT P42858 2/20 0.65
TSHR P16473 4/20 0.59
LMNA P02545 2/20 0.58
RAB9A P51151 2/20 0.58
MAPK1 P28482 1/20 0.58
PKM P14618 2/20 0.56
TTR P02766 2/20 0.56
CA3 P07451 1/20 0.55
CA5A P35218 1/20 0.55
CA5B Q9Y2D0 1/20 0.55
ALDH1A1 P00352 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28114733 0.86 ALDH1A1 (0.72) CA12CA1CA2CA4CA6
SCHEMBL12982799 0.85 LMNA (0.55) CA12CA1CA2CA4CA6
SCHEMBL29688674 0.85 LMNA (0.55) CA12CA1CA2CA4CA6
SCHEMBL31652866 0.85 ALDH1A1 (0.76) CA12CA1CA2CA4CA6
SCHEMBL36091 0.85 ALDH1A1 (0.76) CA12CA1CA2CA4CA6
SCHEMBL2773191 0.84 CA1 (0.74) CA12CA1CA2CA4CA6
SCHEMBL432016 0.83 TSHR (0.62) CA12CA1CA2CA4CA6
SCHEMBL17786825 0.83 ALDH1A1 (0.53) CA12CA1CA2CA4CA6
SCHEMBL426745 0.83 MAPT (0.62) CA12CA1CA2CA4CA6
SCHEMBL1129401 0.82 CYP1A2 (0.77) TSHRLMNAALDH1A1PTGS2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 500 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2516479-B1 NEW INTERNAL AND EXTERNAL DONOR COMPOUNDS FOR OLEFIN POLYMERIZATION CATALYSTS BASF CORP (US) 2016-04-20 EP claimed
US-20260125357-A1 LACTATE ENHANCING COMPOUNDS AND USES THEREOF GLIAPHARM SA (CH) 2026-05-07 US disclosed
EP-4735422-A1 SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF TREATING PHENYLKETONURIA AND OTHER AMINO ACIDURIAS Sanofi (FR) 2026-05-06 EP disclosed
EP-4192454-B1 AZABICYCLO-AMINO-TRIAZINE COMPOUNDS FOR MODULATING SPLICING FOR THE TREATMENT OF NEUROLOGICAL DISEASES SKYHAWK THERAPEUTICS INC (US) 2026-04-22 EP disclosed
EP-3858833-B9 AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREOF AND USE THEREOF TRANSTHERA SCIENCES NANJING INC (CN) 2026-03-11 EP disclosed
EP-4688772-A1 BIARYL DERIVATIVES AND RELATED USES Moma Therapeutics, Inc. (US) 2026-02-11 EP disclosed
US-20260028354-A1 TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS REGENT OF THE UNIV OF MICHIGAN (US) 2026-01-29 US disclosed
EP-3941457-B1 INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION MERCK SHARP & DOHME LLC (US) 2026-01-21 EP disclosed
US-20260014147-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2026-01-15 US disclosed
US-20260015360-A1 BIARYL DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2026-01-15 US disclosed
US-5827869-A Substituted biphenyl isoxazole sulfonamides BRISTOL-MYERS SQUIBB COMPANY (US) 1998-10-27 US disclosed
WO-1997029748-A1 SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES BRISTOL-MYERS SQUIBB COMPANY (US) 1997-08-21 WO disclosed
US-5612359-A Substituted biphenyl isoxazole sulfonamides BRISTOL-MYERS SQUIBB COMPANY (US) 1997-03-18 US disclosed
EP-0702012-A1 Substituted isoxazole sulfonamides and their use as endothelin antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 1996-03-20 EP disclosed
US-5223539-A Antagonist of platelet activating factor G. D. SEARLE & CO. (US) 1993-06-29 US disclosed
WO-1993010077-A1 N,N-DI-ALKYL(PHENOXY)BENZAMIDE DERIVATIVES G.D. SEARLE & CO. (US) 1993-05-27 WO disclosed
EP-0230755-B1 1-PHENYL-3-BENZAZEPINES SMITHKLINE BEECHAM CORPORATION (US) 1990-05-16 EP disclosed
US-4707483-A 1-phenyl-3-benzazepines and their use for treating gastrointestinal motility disorders SMITHKLINE BECKMAN CORPORATION (US) 1987-11-17 US disclosed
EP-0244088-A2 1-Phenyl-3-benzazepine compounds and medicaments containing these compounds for treating gastrointestinal motility disorders SMITHKLINE BEECHAM CORPORATION (US) 1987-11-04 EP disclosed
EP-0230755-A1 1-Phenyl-3-benzazepines SMITHKLINE BEECHAM CORPORATION (US) 1987-08-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015360-A1 BIARYL DERIVATIVES AND RELATED USES POLB, POLA1, POLN CA12 1072/4885CA1 1504/4885CA2 521/4885
US-20260125357-A1 LACTATE ENHANCING COMPOUNDS AND USES THEREOF LDHA, PC, LDHB CA12 791/4885CA1 152/4885CA2 256/4885
US-20260028354-A1 TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ESRRA, ESR2, ESRRB CA12 562/4885CA1 1445/4885CA2 1166/4885
US-20260014147-A1 STAT6 DEGRADERS STAT6, NCOR1, CBR1 CA12 1435/4885CA1 2421/4885CA2 561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.